Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript

🇺🇸 Seeking Alpha (US) —
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript

AI Summary

Tvardi Therapeutics, Inc. discussed Phase 1 data on their TTI-109 STAT3 inhibitor, highlighting the prodrug design, tolerability, and target engagement of the therapeutic candidate. This update marks progress in drug development efforts.

Deals Health Tvardi Therapeutics TTI-109 Phase 1 data STAT3 inhibitor prodrug design drug development

Read original source →